ASTCT

Influence. Innovate. Growth. ASTCT President Margaret MacMillan, MD, MSc, FRCPC and Past President David Porter, MD, discuss the future of ASTCT and the priorities shaping our 2026–2028 Strategic Plan. Watch to learn more: youtube.com/watch?v=yFvlNP…

CAR T therapy is increasingly being used earlier in patients with relapsed or refractory disease and real-world evidence shows efficacy and safety of CAR T therapies. Learn more about new innovations in CAR T with ASTCT's new infographic: ow.ly/mmVr50YruuB

Scientists have identified CSF-1R blockade combined with lenalidomide maintenance therapy as a promising pathway to better progression-free survival following autologous stem cell transplantation (ASCT). Read more on Nucleus: ow.ly/23WK50YMV4e

Whether you're looking for your next opportunity in HCT or transplantation, or you're searching for new talent, ASTCT’s Job Connection has you covered! For a limited time, save 15% on job postings with the code ASTCT15. View ASTCT's Career Center: ow.ly/5Ony50YynNG

The ASTCT + @TheEBMT Scientific Meeting highlights emerging discoveries, evolving technologies and the biological mechanisms shaping the next generation of treatments. Register today to join us in Philadelphia, but hurry, space is limited: astct.org/Meetings/Scien…

Researchers at Bambino Gesù Children’s Hospital in Rome have reported that CD7 may be a viable CAR T-cell target in a subset of relapsed or refractory acute myeloid leukemia, and that fratricide-resistant CD7 CAR T cells can induce deep remissions with an encouraging early safety profile. Read more on Nucleus: #nucleus_body_content" target="_blank" rel="nofollow noopener">astct.org/Nucleus/Articl…

📣 Call for speakers! ASTCT is seeking speakers for the 2026 virtual Clinical Education Conference, taking place Oct. 22-23. The Planning Committee welcomes presenters from a breadth of speaker experiences and backgrounds. Learn more and apply: surveymonkey.com/r/FJ5YWW3

Applications are open for the 2026 International Trainee Observership Program. One international trainee from a low/mid-income country will participate in a 4-week-long observership at @thisisUIC and attend #Tandem27. 📆 Deadline to apply: Sunday, May 24 🔗 ow.ly/60cF50YQIiW

Access the full suite of ASTCT practice guidelines, use built-in clinical calculators and quickly filter between hematopoietic cell transplantation and cellular therapy resources—all within the ASTCT Practice Guidelines app.

A new @ASTCT_Journal guideline outlines best practices regarding nutrition for HSCT recipients and demonstrates that timely referral to a dietitian with expertise in oncology can mitigate weight loss and reduced risk for malnutrition. Read more on @GoHealio: healio.com/news/hematolog…

Join the ASTCT Pharmacy SIG for the Rx-cited: Clinical Conundrums - Highlights in Hematology session on Apr. 30. This session will review emerging data presented at 2025 ASH, evaluate critical updates in hematology research as it relates to HCT and hematologic malignancies & discuss the impact of therapeutic advancements. Register now: ow.ly/m3Fw50YEGxN

📣 Call for speakers! ASTCT is seeking speakers for the 2026 virtual Clinical Education Conference, taking place Oct. 22-23. The Planning Committee welcomes presenters from a breadth of speaker experiences and backgrounds. Learn more and apply: surveymonkey.com/r/FJ5YWW3

In this episode of ASTCT Talks, host Corey Cutler, MD of Dana-Farber Cancer Institute and Harvard University sits down with Nosha Farhadfar, MD, medical director of research for Sarah Cannon Research Institute’s transplant and cellular therapy program at Methodist Healthcare, and Pooja Khandelwal, MD, an associate professor within the division of bone marrow transplantation at Cincinnati Children’s Hospital Medical Center, to discuss adult and pediatric cGVHD treatment perspectives, including approaches, expert practice experiences and new therapeutics. Listen now: ow.ly/S8TJ50YCQnR

ASTCT volunteers play a vital role in shaping the future of hematopoietic cell transplantation and cellular therapy. From committee service to knowledge sharing, your contributions help strengthen our field and improve patient outcomes. We are grateful for all that you do this National Volunteer Week and beyond. #NationalVolunteerWeek

Adenovirus remains an important infectious complication following alloHCT, particularly in the setting of evolving GVHD prophylaxis strategies. This journal club will review a contemporary study evaluating the incidence, timing, and clinical outcomes of adenovirus infection in patients receiving PTCy-based prophylaxis. Register now: ow.ly/fgia50YMT1W

This Transplant Nurses Week, ASTCT honors the dedication, expertise and compassion of transplant nurses who support patients at every step of the hematopoietic cell transplantation and cellular therapy journey. Your commitment advances care, strengthens outcomes and brings hope to patients and families when they need it most. Thank you for the difference you make each day. #TransplantNursesWeek

Hear from Scientific Meeting co-chairs Drs. Pavan Reddy and Nicolaus Kröger on what to expect; this year's meeting showcases new insights on tolerance, tumor immunity, macrophases, B cells, immunotherapies and more. Read more: ow.ly/jmoE50YK75o

#CART cell exhaustion can limit durable responses. This review highlights how immune synapse avidity, mitochondrial repair and mitophagy shape asymmetric cell division, influencing whether CAR T cells become exhausted or persist as memory cells. Read: ow.ly/PGBT50YIU0N

📣 Call for speakers! ASTCT is seeking speakers for the 2026 virtual Clinical Education Conference, taking place Oct. 22-23. The Planning Committee welcomes presenters from a breadth of speaker experiences and backgrounds. Learn more and apply: surveymonkey.com/r/FJ5YWW3

ASTCT's Nucleus is seeking articles written by experts covering the latest in transplantation and cellular therapy. Submit a 500-800-word article on a technical or reflective topic in HCT, cell and gene therapy. All subjects are desired, but topics we are especially interested in include bispecifics, MRD and articles from non-physician perspectives.

Join the ASTCT Pharmacy SIG for the Rx-cited: Clinical Conundrums - Highlights in Hematology session on Apr. 30. This session will review emerging data presented at 2025 ASH, evaluate critical updates in hematology research as it relates to HCT and hematologic malignancies & discuss the impact of therapeutic advancements. Register now: ow.ly/m3Fw50YEGxN